Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PDS Biotechnology Corp (PDSB)

PDS Biotech to host October 15 KOL event on PDS0301 for colorectal liver cancer

Neutral Impact 2 of 5 other Written later

PDS Biotechnology announced a virtual key opinion leader event on October 15, 2026, at 8:00 AM ET. Investigator Jonathan M. Hernandez, M.D., of the National Cancer Institute, will join management to discuss clinical outcomes from the PDS0301 Phase 2 trials, focusing on metastatic colorectal cancer. The filing reports no financial results, so the event itself is the news for shareholders.

Key points

  • Virtual KOL event is set for Thursday, October 15, 2026, at 8:00 AM ET, followed by a live question and answer session
  • Speaker is Jonathan M. Hernandez, M.D., Investigator, Surgical Oncology Program, NCI Center for Cancer Research
  • Discussion covers PDS0301 Phase 2 clinical outcomes, with a focus on the metastatic colorectal cancer (mCRC) cohort

The filing

CompanyPDS Biotechnology Corp (PDSB)
Form8-K, current report
Filed with the SECOct 6, 2026, 8:05 AM ET
Accession number0001140361-26-038728

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.